A METHOD TO MEASURE IGF TYPE I RECEPTOR AND INSULIN RECEPTOR ISOFORM EXPRESSION

Invention Summary:

It has been generally accepted that although insulin (IR) and the insulin-like growth factor (IGF-IR) receptor pathways have similar structure and function, they exert different physiological actions in disease and non-disease states. Studies have shown that, in normal states, IR is responsible for mediating downstream targets involved in metabolic functions. In contrast, the IGF-IR mediates the activation of target genes involved in cell growth and differentiation. It has recently become clear that there exists multiple isoforms of signaling receptors, which include hybrid receptors, through which insulin and insulin-like growth factor can exert their physiological actions. However, there is a lack of a current method to differentiate between various isoforms within a particular tissue. Thus, the design of a method which allows one to distinguish between relative levels of insulin and IGF-IR receptor isoform expression will be extremely valuable as a predictive tool for IGF and insulin sensitivity in various cells and/or tissues. Currently, there exists no quantitative method to measure relative expression levels of all insulin and insulin-like growth factor receptor isoforms within a particular cell or tissue. The availability of such an assay, will allow researchers to predict the presence of hybrid receptors, as well as specific ligand-receptor interactions within a particular cell. Therefore, a method to quantitatively measure relative and absolute levels of IGF and IR receptors has been developed.

Market Applications:

  • Prediction of insulin and IGF sensitivity of various cell lines or tissue
  • Prediction of hybrid receptors
  • Diagnostic tool to predict treatment strategies for cancer, diabetes and metabolic diseases
  • Use in the analysis of animal models for diseases such as diabetes
  • The development of new specific drugs for the treatment of cancer and diabetes

Intellectual Property & Development Status:

United States Patent Number 8,377,655 granted on February 19, 2013

Rutgers ID: S07-23
Category(s):
Life Sciences
Contact:
Fred Banti
Assistant Licensing Manager
fb258@ored.rutgers.edu
Inventors:
Teresa Wood
Anne Rowzee
Keywords: